By Calliditas Therapeutics’ American depositary receipts jumped more than 70% premarket on Tuesday after a nearly $1.1 billion takeover bid from a Japanese conglomerate.
Calliditas Therapeutics’ American depositary receipts jumped more than 70% premarket on Tuesday after a nearly $1.1 billion takeover bid from a Japanese conglomerate.
Comments